Dr. Toru Uchiyama works on the development and clinical application of gene and cell therapies. His experience includes clinical studies and investigator-initiated trials of hematopoietic stem cell gene therapy for primary immunodeficiency diseases such as chronic granulomatous disease and Wiskott-Aldrich syndrome. He has also been involved in CAR-T cell therapy for refractory leukemia, AAV-based in vivo gene therapy for neurological disorders, and genome editing-based gene therapy for primary immunodeficiency diseases.

Dr. Wenshi Wang is Senior Vice President, Technology & Operations at FosunKairos. She brings extensive international and U.S. institutional experience in cell and gene therapy-driven biotech and biopharma drug development, with prior experience across organizations including HemaCare, Kite Pharma, Sangamo Therapeutics, and Metagenomi. In her current role, she supports the advancement of cell and gene therapy development and operational excellence at FosunKairos.

Dr. Somanath Bhat is a Senior Research Scientist and Chair of the Institutional Biosafety Committee at the National Measurement Institute (NMI), Sydney, Australia, specialising in digital PCR, molecular diagnostics, and measurement science. With more than 20 years of experience, his work focuses on developing SI-traceable digital PCR measurements, certified nucleic acid (DNA/RNA) reference materials, and quality assurance programs to improve the accuracy and comparability of genetic testing. Through collaborations with national and international partners, the group develops reference materials that support the global harmonisation of genetic measurements and facilitate the broader adoption of ddPCR in diagnostics and biotechnology.

Associate Professor Bing Yu is a molecular geneticist and clinical scientist at NSW Health Pathology and Royal Prince Alfred Hospital in Sydney, Australia. His work bridges translational research, genomic diagnostics, and precision medicine, with a focus on somatic cancer testing in solid tumours such as lung, breast, melanoma, and colorectal cancers. His research supports more precise treatment selection, drug resistance identification, minimal residual disease monitoring, and recurrence detection through the clinical use of genomic biomarkers.

Dr. Pratt is the Biopharma Segment Marketing Manager at Bio-Rad Laboratories. In this role, she works with leaders in the biotech and pharmaceutical industries to understand how Bio-Rad can accelerate drug discovery and development in new therapeutic areas. She is a recognized expert in chromatography and protein purification, and serves as a regular panelist at conferences, seminars, and webinars. Dr. Pratt holds a PhD in Biological Chemistry from the University of Texas Southwestern Medical Center.

Dr. Yong Yang is the director of analytical method development at Fosun Kairos. After he was rewarded bachelor degree of medicine and Ph.D. of biochemistry and molecular biology at Fudan University, he finished his postdoc training at University of Pittsburgh. He brings not only extensive research experience but also the drug development expertise in cell and gene therapy biotech.

Dr. Yong Yang is the director of analytical method development at Fosun Kairos. After he was rewarded bachelor degree of medicine and Ph.D. of biochemistry and molecular biology at Fudan University, he finished his postdoc training at University of Pittsburgh. He brings not only extensive research experience but also the drug development expertise in cell and gene therapy biotech.

Dr. M. R. Vishnuraj is a scientist at ICAR-National Meat Research Institute, Hyderabad, where he heads the Meat Species Identification Laboratory, an ISO 17025:2017 NABL-accredited facility and FSSAI referral laboratory. With over a decade of experience in molecular diagnostics and food authenticity, his work focuses on species authentication, adulteration detection, and molecular method development. He has developed highly sensitive ddPCR assays for trace-level detection and quantification in animal-origin foods, supporting food safety, regulatory compliance, and advanced molecular research.

Dr. Tomohiro Kubo has served as CEO of TL Genomics Inc. since 2015, overseeing technology development and business growth. He received his B.S. and Ph.D. in Biology from Kyoto University, followed by postdoctoral research at Columbia University in New York. Before joining TL Genomics, he spent five years in business development, licensing, technology transfer, and marketing at a Japanese biotech company, bringing together scientific expertise and commercial experience in biotechnology.

Dr. Saranyoo Ponnikorn is Director of the Center for Scientific Equipment for Advanced Research at Thammasat University and holds a PhD in Biochemistry from Mahidol University. He brings more than a decade of experience across genetics, molecular and cell biology, biochemistry, and stem cell biology. He also contributes to national precision medicine committees under Thailand’s Ministry of Public Health and is a co-founder of biotechnology ventures focused on extracellular vesicles, regenerative aesthetics, and functional health products. His research spans precision medicine, omics technologies, extracellular vesicle therapeutics, and translational regenerative medicine, with a focus on innovative approaches for disease management, skin therapeutics, and longevity applications.

Dr. Akira Yokoi is a gynecologic oncologist and translational scientist specializing in ovarian cancer biomarker discovery. His research focuses on extracellular vesicles for early cancer detection and the development of advanced EV-based diagnostic models. He has published influential studies in high-impact journals and continues to advance novel nanotechnologies for extracellular vesicle analysis. At Nagoya University, he leads translational research that combines clinical samples with advanced molecular and bioinformatics approaches.

Professor Wanil Kim is an Associate Professor at the College of Medicine, Gyeongsang National University, South Korea. His research focuses on aging biology, telomere dynamics, cellular senescence, and molecular mechanisms of age-related diseases. He received his PhD in Molecular Life Sciences from POSTECH and completed postdoctoral training at the University of Texas Southwestern Medical Center. His current work uses ddPCR for quantitative molecular analysis, including telomerase activity, TERT isoform profiling, and biomarker discovery in aging and neurodegenerative diseases.

Dr. Goh Liuh Ling is the Laboratory Director and Senior Principal Scientific Officer at the Molecular Diagnostic Laboratory, Centre for Precision and Genomic Medicine, Tan Tock Seng Hospital. She leads clinical molecular diagnostics, research, and biobanking, and plays an active role in advancing precision medicine in Singapore through national initiatives such as PRECISE. Her work focuses on genomic testing strategies, liquid biopsy applications, and multi-omics approaches for cancer, supported by expertise in next-generation sequencing and translational research.

Dr. Salil Vaniawala is a molecular oncology and genomic diagnostics expert in India with more than 23 years of experience in clinical and research genetics. He is the founder and owner of SN Genelab, Gujarat’s first NABL-accredited and ISO 15189-certified genetic laboratory, and one of India’s advanced genomic institutions. His work spans cancer genomics, liquid biopsy, tumor mutational profiling, and precision oncology. He has authored over 100 peer-reviewed publications, contributed to Indian population-specific genomic datasets, and helped expand access to precision medicine through more than one million genetic tests processed under SN Genelab’s leadership.

Professor Jinhwa Hong, MD, PhD, is a professor of Gynecologic Oncology and Director of the Women's Cancer Center at Korea University Guro Hospital, South Korea. He received his MD and PhD from Korea University and completed advanced clinical and research training at MD Anderson Cancer Center and the University of California, Irvine. His work focuses on gynecologic cancers, precision oncology, molecular diagnostics, and translational cancer research. He is an active member of several international gynecologic oncology societies and is recognized as a leading expert in the research and management of gynecologic malignancies.

Dr. Stephanie Yu is a clinical lecturer in the Department of Chemical Pathology at The Chinese University of Hong Kong. Her research focuses on liquid biopsy, particularly the biology and clinical applications of cell-free DNA. She has contributed to the development of size-based approaches for noninvasive prenatal testing, as well as diagnostic tools for single-gene disorders and preeclampsia. Her work has been published in leading journals, and she holds numerous patents in cfDNA technologies that have been successfully translated into licensed applications.

Dr. Knut Woltjen is based at Kyoto University’s Center for iPS Cell Research and Application. He holds a PhD in Molecular Genetics and specializes in stem cell gene editing. During his postdoctoral work, he used the piggyBac transposon to create the first footprint-free human and mouse iPS cells. His laboratory continues to advance piggyBac-based differentiation and precision editing, while also developing genome and epigenome editing methods to support cell therapy research and the study of human health, disease, and evolution.